Coalition for Mercury Free Drugs v. Leavitt

District Court, District of Columbia·Decided June 29, 2010·No. Civil Action No. 2009-0015·Published

Opinion

UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA

)

THE COALITION FOR MERCURY-FREE ) DRUGS, et al., )

)

Plaintiffs, )

)

v. ) Civil Action No. 09-0015 (RBW)

)

KATHLEEN SEBELIUS, 1 SECRETARY ) OF HEALTH AND HUMAN SERVICES, et al., )

)

Defendants. )

__________________________________________)

MEMORANDUM OPINION

The plaintiffs, the Coalition for Mercury-Free Drugs (“Mercury-Free”), and several named individuals who are also the principal officers of Mercury-Free, bring this action against the Secretary of Health and Human Services and the Commissioner of the Food and Drug Administration ("FDA") in their official capacities, alleging injuries arising from the defendants' approval of the use of Thimerosal, a mercury-based chemical compound used in pharmaceutical products, such as vaccines, to prevent the growth of bacteria or fungi. See Complaint ("Compl.") ¶¶ 3-7, 83-100. Currently before the Court are several motions, including the defendants' motion to dismiss the plaintiffs' complaint pursuant to Federal Rule of Civil Procedure 12(b)(1) on the ground that the plaintiffs cannot allege a concrete, imminent injury caused by the defendants’ actions sufficient to invoke the Article III jurisdiction of this Court, see Memorandum in Support

1 Kathleen Sebelius, the current Secretary of Health and Human Services, and Margaret Hamburg, the current Commissioner of the Food and Drug Administration, have been substituted for the originally named defendants in this action pursuant to Federal Rule of Civil Procedure 25(d).

of Motion to Dismiss ("Defs.' Mem.") at 2, which the plaintiffs oppose. 2 See Plaintiffs' Memorandum of Law in Opposition to the Defendants' Motion to Dismiss ("Pls.' Opp'n"). In addition to the defendants' motion to dismiss, the Court also considered the following pending motions and related filings in resolving the defendants’ motion to dismiss: (1) the plaintiffs' motion to conduct jurisdictional discovery, see Plaintiffs' Motion for Leave to Conduct Jurisdictional Discovery (“Pls.' Mot. Re: Discovery”); Plaintiffs' Memorandum of Points and Authorities in Support of its Motion for Leave to Conduct Discovery Limited to the Issue of Jurisdiction ("Pls.' Mem. Re: Discovery"), which the defendants oppose, see Defendants' Opposition to Plaintiffs' Motion for Leave to Conduct Discovery Limited to the Issue of Jurisdiction ("Defs.' Opp'n Re: Discovery"); 3 (2) the defendants' motion for a protective order, see Motion for a Protective Order; Memorandum in Support of Defendants' Motion for Protective Order; and (3) three motions by the plaintiff seeking leave to supplement the record, see Motion for Leave to Supplement Record [Oct. 9, 2009] ("Pls.' Mot. to Supplement I"), Motion for Leave to Supplement Record [Oct. 19, 2009] ("Pls.' Mot. to Supplement II"), Motion for Leave to Supplement Record [March 17, 2010] ("Pls.' Mot. to Supplement III"), which the defendants oppose, see Defendants’ Opposition to Plaintiffs’ Motions for Leave to Supplement

2 Because of their relevance to the issues raised in the defendants' motion to dismiss, the Court also considered the following documents in resolving the motion: the Defendants' Motion to Dismiss; the Reply Memorandum in Support of Defendants' Motion to Dismiss ("Defs.' Reply"); the Plaintiffs' Motion for a Preliminary Injunction ("Pls.' Mot. Re: Injunction"); the Memorandum of Points and Authorities in Support of Plaintiffs’ Motion for Preliminary Injunction (“Pls.’ Mem. Re: Injunction”); the Memorandum in Opposition to Plaintiffs' Motion for Preliminary Injunction (“Defs.’ Opp’n Re: Injunction”); and the Plaintiffs' Motion for Leave to Conduct Jurisdictional Discovery. 3 The Court also considered the Petitioners' [sic] Reply to Defendants' Opposition to Plaintiffs' Motion for Leave to Conduct Discovery Limited to the Issue of Jurisdiction ("Pls.' Reply Re: Discovery") in resolving the motion to dismiss.

the Record ("Defs.' Opp'n Re: Leave to Supplement"). 4 For the reasons that follow, the Court finds that the plaintiffs do not have standing to bring this lawsuit and accordingly must grant the defendants' motion to dismiss the plaintiffs’ complaint under Federal Rule of Civil Procedure 12(b)(1). In concluding that the plaintiffs lack standing, the Court considered their three motions for leave to supplement the record over the defendants' objection. The Court also concludes that the plaintiffs' request for jurisdictional discovery was not narrowly tailored to produce information relevant to the issue of standing and thus ordering jurisdiction discovery is not warranted. And because the plaintiffs' lack of standing, the Court finds that the issuance of a protective order is unnecessary.

I. BACKGROUND

Thimerosal has been used in the United States since the 1930s and was subsequently determined by the FDA to be safe and effective when used as a vaccine preservative. 5 FDA, Thimerosal in Vaccines (March 31, 2010). 6 Nevertheless, in 1999, in furtherance of its overall aim to reduce all human exposure to mercury, the Public Health Service established a goal to remove Thimerosal from vaccines routinely recommended for children. See Defs.' Mem at 4. Consequently, there are now mercury-free alternatives for all vaccines routinely recommended for both children and adults. Id.

4 The docket reflects that in the early hours of April 1, 2010, the plaintiffs filed three additional supplemental memoranda backdated to March 31, 2010, the day the Court issued its Order resolving the motions addressed in this Memorandum Opinion. Given that the Court resolved the motions prior to the conspicuously backdated supplemental memoranda being filed, they were untimely filed and were not considered by the Court. 5 It should be noted that vaccines that are packaged in single-dose vials do not require any preservative and thus will not contain any mercury-based preservative. See id., Ex. A, (FDA Citizen Petition Denial at 17). The presence of Thimerosal in vaccines is therefore only at issue where multi-dose vials are utilized, i.e., where multiple patients' doses are extracted from a common vial. See id., Exhibit A, (FDA Citizen Petition Denial at 4). 6 Available at http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/VaccineSafety/ ucm096228.htm (last accessed April 21, 2010).

The plaintiffs oppose any use of mercury-based preservatives, such as Thimerosal, in vaccines contending that it is the cause of a variety of health problems, including the development of autism and other brain development disorders in children when either children or pregnant mothers are exposed to it. Compl. ¶¶ 68-73. On August 10, 2007, Mercury-Free filed a citizen petition seeking to have the FDA: (1) proscribe the use of Thimerosal-containing vaccines or other similarly preserved medical products for certain “susceptible” classes; (2) withdraw its approval of or revoke the license for the use of these vaccines; (3) issue an immediate recall and destruction of these vaccines; (4) alter the warning labels and informed consent policies for these vaccines; and (5) alter the FDA’s policy stance on these vaccines as a whole. See generally, Defs.' Mem. at 1 (referring to the citizen petition, see Paul King, PhD, et al., Citizen Petition Requesting Certain Actions with Respect to Vaccines and Other Drug Products, Containing Added Mercury, in Order to Reduce the Health Risk to Susceptible Fetuses, Newborns, Children, Adolescents and Adults (Aug. 24, 2007), http://mercury- freedrugs.org/docs/070824_CoMeDCitizenPetitionPart2.pdf). The FDA denied the petition on November 21, 2008, asserting that Mercury-Free's contentions were supportable by neither law nor science and the pharmaceutical products currently on the market containing mercury preservatives are safe. Defs.' Mem. at 1. Seeking to challenge the FDA's denial of their petition, the plaintiffs filed their complaint with this Court.

Free access — add to your briefcase to read the full text and ask questions with AI

Coalition for Mercury Free Drugs v. Leavitt, (D.D.C. 2010).

Coalition for Mercury Free Drugs v. Leavitt (Coalition for Mercury Free Drugs v. Leavitt) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

City of Los Angeles v. Lyons
461 U.S. 95 (Supreme Court, 1983)
Whitmore Ex Rel. Simmons v. Arkansas
495 U.S. 149 (Supreme Court, 1990)
United States v. Gaubert
499 U.S. 315 (Supreme Court, 1991)
Lujan v. Defenders of Wildlife
504 U.S. 555 (Supreme Court, 1992)
Kokkonen v. Guardian Life Insurance Co. of America
511 U.S. 375 (Supreme Court, 1994)
Federal Election Commission v. Akins
524 U.S. 11 (Supreme Court, 1998)
Summers v. Earth Island Institute
555 U.S. 488 (Supreme Court, 2009)
Alamo, Tony v. Clay, Jasper R.
137 F.3d 1366 (D.C. Circuit, 1998)
D&F Afonso Realty Trust v. Garvey
216 F.3d 1191 (D.C. Circuit, 2000)
Young America's Foundation v. Gates
573 F.3d 797 (D.C. Circuit, 2009)
National Treasury Employees Union v. United States
101 F.3d 1423 (D.C. Circuit, 1996)
Common Cause v. Federal Election Commission
108 F.3d 413 (D.C. Circuit, 1997)
Tummino v. Torti
603 F. Supp. 2d 519 (E.D. New York, 2009)
Baptist Memorial Hospital v. Johnson
603 F. Supp. 2d 40 (District of Columbia, 2009)
Hollingsworth v. Duff
444 F. Supp. 2d 61 (District of Columbia, 2006)